How to Survive the Coronavirus Sell-Off

Major indices have been dropping rapidly for the last week on fears of widespread economic disruption related to the coronavirus outbreak. Today, Wealth Daily contributor Samuel Taube is examining “coronavirus stocks” — safe places to continue growing your money during this sell-off. Major indices have been dropping rapidly for the last week on fears of widespread economic disruption related to the coronavirus outbreak. Today, Wealth Daily contributor Samuel Taube is examining “coronavirus stocks” — safe places to continue growing your money during this sell-off. [Energy and Capital logo] How to Survive the Coronavirus Sell-Off By Samuel Taube Written Mar. 08, 2020 A few months ago, if you had asked the analysts at Angel what would trigger the next market downturn, we would have given you a variety of answers — the U.S.-China trade war, erratic monetary policy, something like that. None of us could have predicted that a new, rapidly spreading respiratory virus from China would cause the next crash. [coronavirus stocks, 1] But as you can see above, the Dow and the S&P 500 shed almost 10% in a matter of days due to fears of the economic impact of the coronavirus outbreak. It just goes to show that the "black swan" events that cause large sell-offs are often completely unpredictable. And this sell-off appears to be justified. The coronavirus, which didn’t exist a few months ago, has infected almost 100,000 people around the world and killed almost 3,000. It has brought China, the world’s most populous country and largest economy by some metrics, to a standstill. And public health experts believe that the outbreak is still in its early stages. That means the sell-off might still be in its early stages, too. With all of this in mind, today we’re looking at some bright spots in the market: the “coronavirus stocks” that will allow you to keep growing your money while the current crisis plays out. The Death of Cable This month, instead of tossing your cable bill, you might want to save it, maybe even get it framed. Who knows, by next year it could be a historical relic. Because by 2020, cable companies could be completely obsolete... They’ll be pushed out by newer, better, cheaper technologies. I’ve found a company that’s leading the charge. And it’s still trading for less than $10. But hurry — this stock won’t stay in buying range for long. Don’t waste any more time. [Click here to get all the details.]( Big Tech It stands to reason the stocks that will be least affected by the coronavirus outbreak are those with the least exposure to China. And it’s hard to think of a better example of a set of China-free stocks than Big Tech. Microsoft (NASDAQ: MSFT) and Alphabet (NASDAQ: GOOG) are both shut out of the Chinese market already; citizens of the country use homegrown alternatives like 21Vianet and Baidu, respectively. These two stocks have not necessarily been winners for the last couple of years. In fact, they’ve been under heavy selling pressure amid regulatory scrutiny. But this selling pressure has brought down their valuations to more comfortable levels. As you can see, neither of these stocks has posted losses during the recent coronavirus outbreak, and they’ve both handily outperformed the S&P 500. That’s partially because they’re not exposed to coronavirus-related risks, but it’s also because they’re just compelling companies in their own right. Both have posted below average price-to-book ratios and double-digit earnings growth in the last year. [coronavirus stocks, 2]These two stocks should serve as relative safe havens from coronavirus-related selling. But there are other coronavirus stocks that could actually benefit from the crisis... Consumer Staples The coronavirus outbreak may not have reached pandemic status yet, but it has worried consumers around the world enough to spark frenzied runs to pharmacies, department stores, and grocery stores. Here in the U.S., where there have only been a few dozen confirmed cases, retailers are running out of surgical masks, hand sanitizer, and other disease prevention supplies. That’s bad news for the population, but it’s very good news for the consumer staples companies that make these products. [coronavirus stocks, 3] As you can see above, Clorox (NYSE: CLX) and Johnson & Johnson (NYSE: JNJ) have both posted positive returns since the start of the coronavirus outbreak. In fact, Clorox’s growth has only accelerated as the rest of the market has sold off. These two companies also have comfortably low valuations and strong earnings growth; they’d be worth considering even if they weren’t being boosted by coronavirus fears. And there’s another type of coronavirus stock that provides an even more direct play on the crisis… [Batteries Now Obsolete?]( The “Tesla Killer” is here American-made "Blue Gas" has Elon Musk furious! The tiny stock making it possible trades for just a few bucks... And is set to trade higher than Tesla within the next few months. [See why stunning 90,900% growth is just ahead](. Biotech Stocks One of the scariest things about this virus is the fact that it was completely unknown to science before December of last year. There’s no vaccine and no medication protocol for it. But a number of publicly traded U.S. biotech companies are working on developing vaccines and treatments. Those that have made headway have seen substantial jumps in their share prices. RNA-focused drugmaker Moderna (NASDAQ: MRNA) saw its price spike by roughly 50% in a single day after it announced that it had submitted a coronavirus vaccine candidate to the National Institutes of Health for clinical trials. [coronavirus stocks, 4] Does that mean you should buy Moderna? Probably not. The good news about its coronavirus vaccine is priced in by now. In fact, you can see a slight pullback in the graph above. The next big coronavirus-related gains from the biotech sector will be made by a company that is currently developing a novel treatment or vaccine and hasn’t submitted it to the authorities for testing yet. Problem is, unless you have a network of doctors and biotech industry experts working for you, it’s nigh-impossible to monitor all the goings-on of small, early-stage biotech companies that are developing these sorts of experimental products. But [Topline Trader](editor Jason Stutman has solved that problem for you. He has a massive professional network in the biotech industry that apprises him of every major investment catalyst in the early-stage biotech industry, and he shares those catalysts with subscribers, helping them earn massive gains. [Click here to learn more](. Until next time, [Monica Savaglia] Samuel Taube Samuel Taube brings years of experience researching ETFs, cryptocurrencies, muni bonds, value stocks, and more to [Wealth Daily](. He has been writing for investment newsletters since 2013 and has penned articles accurately predicting financial market reactions to Brexit, the election of Donald Trump, and more. Samuel holds a degree in economics from the University of Maryland, and his investment approach focuses on finding undervalued assets at every point in the business cycle and then reaping big returns when they recover. To learn more about Samuel, [click here](. Enjoy reading this article? [Click here]( to like it and receive similar articles to read! Browse Our Archives [Crude Oil Is Still a Screaming Buy]( [What Investors Should Know About Socialism in the White House]( [Investing in Oil Has Changed, Will You Sink or Swim?]( [Even a Dead Cat Will Bounce If You Drop It From High Enough…]( [Oil is a Screaming Buy]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Energy and Capital](, Copyright © 2020, [Angel Publishing LLC](. All rights reserved. 111 Market Place #720 Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Energy and Capital as well as a link to www.energyandcapital.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Energy and Capital]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.